Blood transfusions for pregnant women with sickle cell disease
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study tests whether giving regular blood transfusions during early pregnancy can help prevent complications for women with sickle cell disease. If you are between 6 and 20 weeks pregnant, you may join to see if this treatment improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and over 18 years old
- You have been diagnosed with any type of sickle cell disease (like HbSS, HbSC, or HbSβ thalassemia)
- You are currently between 6 and 20 weeks pregnant
- You are not already on regular blood transfusions before this pregnancy
- You have not had a dangerous reaction to blood transfusions called DHTR with hyperhemolysis
- You are able to understand the study and give your okay, and if you have private insurance, it must approve the transfusions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is developing a risk assessment tool to help predict complications in pregnant women with sickle cell disease. It reviews medical records from women who have received prenatal care and given birth at participating hospitals.
This study looks at whether certain genes make people with sickle cell disease more likely to develop an immune reaction to blood transfusions. It aims to help doctors predict transfusion risks and improve care.
This study looks at whether regular red blood cell exchange (a treatment that replaces sickled red blood cells with healthy ones) can reduce blood clotting and inflammation in people with sickle cell disease. It aims to see if this treatment helps protect your blood vessels.
This early-phase study tests whether a “half-matched” donor bone marrow transplant, with special medicines to calm the immune system before transplant, can improve outcomes for people with sickle cell disease. It may help high-risk patients who have frequent complications and don’t have a fully matched donor.
This trial tests a stem cell transplant from a half-matched donor using a strong conditioning regimen and a drug called defibrotide to protect organs. It aims to cure sickle cell disease in patients who have had serious complications like stroke, chest syndrome, or frequent pain episodes.
This trial tests whether a half-matched (haploidentical) blood stem cell transplant can treat adults with severe sickle cell disease. It may help reduce serious complications and improve survival, but it requires a fit health status and specific donor and medical conditions.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.